{"id":"NCT03635489","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","officialTitle":"A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-15","primaryCompletion":"2021-05-26","completion":"2023-05-11","firstPosted":"2018-08-17","resultsPosted":"2023-03-17","lastUpdate":"2024-10-03"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":[{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bevacizumab + Paclitaxel + Carboplatin","type":"EXPERIMENTAL"},{"label":"Placebo + Paclitaxel + Carboplatin","type":"PLACEBO_COMPARATOR"}],"summary":"This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly diagnosed, previously untreated Stage III or Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants whose disease has not progressed after six cycles of paclitaxel and carboplatin with either bevacizumab or placebo will continue treatment with either bevacizumab or placebo until disease progression, unacceptable toxicity, or a maximum of 22 cycles, whichever occurs first.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)","effectByArm":[{"arm":"Placebo + Paclitaxel + Carboplatin","deltaMin":12.32,"sd":null},{"arm":"Bevacizumab + Paclitaxel + Carboplatin","deltaMin":22.57,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"},{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":16,"countries":["China"]},"refs":{"pmids":["38872480","37185961"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":50},"commonTop":["Alopecia","Anaemia","Neutrophil count decreased","White blood cell count decreased","Platelet count decreased"]}}